@prefix dcterms: .
@prefix ns1: .
@prefix this: .
@prefix sub: .
@prefix schema: .
@prefix np: .
@prefix rdf: .
@prefix nt: .
@prefix xsd: .
@prefix rdfs: .
@prefix orcid: .
@prefix bl: .
@prefix npx: .
sub:Head {
this: np:hasAssertion sub:assertion;
np:hasProvenance sub:provenance;
np:hasPublicationInfo sub:pubinfo;
a np:Nanopublication .
}
sub:assertion {
bl:category bl:Disease .
sub:association rdf:object ;
rdf:predicate bl:treats;
rdf:subject ;
a rdf:Statement;
rdfs:label "lucentis is indicated for the treatment of patients with lucentis a vascular endothelial growth factor vegf inhibitor is indicated for the treatment of patients with neovascular wet age related macular degeneration amd 1 1 macular edema following retinal vein occlusion rvo 1 2 diabetic macular edema dme 1 3 diabetic retinopathy dr 1 4 myopic choroidal neovascularization mcnv 1 5";
bl:association_type bl:ChemicalToDiseaseOrPhenotypicFeatureAssociation;
bl:provided_by ;
bl:relation schema:TreatmentIndication .
bl:category bl:Drug .
}
sub:provenance {
sub:assertion ns1:wasAttributedTo orcid:0000-0002-1468-3557 .
}
sub:pubinfo {
sub:sig npx:hasAlgorithm "RSA";
npx:hasPublicKey "MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB";
npx:hasSignature "iUTGnqIysUkRjeKNXrcraQPCTSSXTOOAox/erxIwWH0oXLeIE0x9IgggRvrc7h540/eSx7UoWFvldBRzziSQohMMGLaiZJZUc7omISA2vlhK0TBnu5TP5STjA/lFkWfkdB0GkfwXjnN/AjxTq8fZuK18Us9Q9Hg0r8V9Q+T4lPU=";
npx:hasSignatureTarget this: .
this: dcterms:created "2021-07-03T15:14:13.406+02:00"^^xsd:dateTime;
dcterms:creator orcid:0000-0002-1468-3557;
nt:wasCreatedFromProvenanceTemplate ;
nt:wasCreatedFromPubinfoTemplate ;
nt:wasCreatedFromTemplate .
}